Glaukos (GKOS) to Release Earnings on Thursday

Glaukos (NYSE:GKOS) is projected to issue its quarterly earnings data after the market closes on Thursday, February 20th. Analysts expect the company to announce earnings of ($0.38) per share and revenue of $100.72 million for the quarter. Parties that are interested in participating in the company’s conference call can do so using this link.

Glaukos Stock Performance

Glaukos stock opened at $153.00 on Wednesday. The stock has a market cap of $8.44 billion, a P/E ratio of -50.66 and a beta of 1.04. The company has a current ratio of 5.54, a quick ratio of 4.71 and a debt-to-equity ratio of 0.19. The stock has a 50 day moving average of $151.95 and a 200-day moving average of $138.62. Glaukos has a 52 week low of $83.90 and a 52 week high of $163.71.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on GKOS. UBS Group began coverage on Glaukos in a research note on Friday, December 6th. They set a “buy” rating and a $182.00 price objective on the stock. Truist Financial increased their target price on Glaukos from $152.00 to $185.00 and gave the stock a “buy” rating in a research report on Wednesday, December 18th. Wells Fargo & Company raised their price target on Glaukos from $145.00 to $153.00 and gave the company an “overweight” rating in a report on Wednesday, December 11th. BTIG Research lifted their target price on Glaukos from $140.00 to $149.00 and gave the stock a “buy” rating in a report on Tuesday, November 26th. Finally, JPMorgan Chase & Co. lifted their target price on Glaukos from $130.00 to $145.00 and gave the stock an “overweight” rating in a report on Tuesday, November 5th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $151.08.

Insiders Place Their Bets

In other news, Director Gilbert H. Kliman sold 2,000 shares of Glaukos stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $144.01, for a total transaction of $288,020.00. Following the completion of the sale, the director now directly owns 32,336 shares in the company, valued at $4,656,707.36. The trade was a 5.82 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Joseph E. Gilliam sold 3,328 shares of the firm’s stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $149.85, for a total value of $498,700.80. Following the completion of the transaction, the chief operating officer now directly owns 102,169 shares in the company, valued at $15,310,024.65. The trade was a 3.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 15,328 shares of company stock worth $2,289,521. 6.40% of the stock is currently owned by company insiders.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.